INTELLIA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
INTELLIA THERAPEUTICS, INC. (NTLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.30% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.30%, a 4.88% increase year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.60%, a 12.20% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 3.90%, a 2.50% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.10%, a 4.65% decline year-over-year.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.10%, a 2.38% decline from fiscal 2024.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 4.55% decline from fiscal 2023.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.40%, a 131.58% increase from fiscal 2022.
- INTELLIA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.90%, a 90.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-06 | 3.70% 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 3.60% 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | 4.10% 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 3.90% 10-Q · filed 2025-11-06 | 4.10% 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 4.10% 10-Q · filed 2026-08-06 | 4.10% 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 4.10% 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | 4.20% 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 4.00% 10-Q · filed 2025-11-06 | 4.20% 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 4.30% 10-Q · filed 2025-08-07 | 4.20% 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 4.20% 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 4.40% 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 4.40% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 4.10% 10-Q · filed 2024-08-08 | 4.40% 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | 4.40% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 1.90% 10-K · filed 2025-02-27 | |||
| 2022-09-30 | 1.90% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 3.40% 10-Q · filed 2023-08-03 | 1.90% 10-Q · filed 2023-08-03 | ||
| 2022-03-31 | 1.60% 10-Q · filed 2023-05-04 | |||
| 2021-12-31 | 1.00% 10-K · filed 2024-02-22 | |||
| 2021-09-30 | 1.00% 10-Q · filed 2022-11-03 | 0.90% 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | 1.10% 10-Q · filed 2022-08-04 | 0.90% 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | 0.90% 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | 0.80% 10-K · filed 2023-02-23 | |||
| 2020-09-30 | 0.40% 10-Q · filed 2021-11-04 | 0.90% 10-Q · filed 2021-11-04 | ||
| 2020-06-30 | 0.40% 10-Q · filed 2021-08-05 | 0.90% 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | 1.00% 10-Q · filed 2021-05-06 | |||
| 2019-12-31 | 2.10% 10-K · filed 2022-02-24 | |||
| 2019-09-30 | 1.60% 10-Q · filed 2020-11-05 | 2.20% 10-Q · filed 2020-11-05 | ||
| 2019-06-30 | 2.10% 10-Q · filed 2020-08-06 | 2.40% 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | 2.60% 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | 2.70% 10-K · filed 2021-02-26 | |||
| 2018-09-30 | 2.80% 10-Q · filed 2019-10-31 | 2.60% 10-Q · filed 2019-10-31 | ||
| 2018-06-30 | 2.80% 10-Q · filed 2019-08-01 | 2.60% 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | 2.50% 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | 2.00% 10-K · filed 2020-02-27 | |||
| 2017-09-30 | 1.90% 10-Q · filed 2018-10-31 | 1.90% 10-Q · filed 2018-10-31 | ||
| 2017-06-30 | 1.50% 10-Q · filed 2018-08-01 | 1.90% 10-Q · filed 2018-08-01 | ||
| 2017-03-31 | 1.90% 10-Q · filed 2018-05-01 | |||
| 2016-12-31 | 1.30% 10-K · filed 2019-02-27 | |||
| 2016-09-30 | 1.30% 10-Q · filed 2017-10-31 | |||
| 2016-06-30 | 1.30% 10-Q · filed 2017-08-01 | |||
| 2016-03-31 | 1.30% 10-Q · filed 2017-05-02 | |||
| 2015-12-31 | 1.50% 10-K · filed 2018-03-14 | |||
| 2015-09-30 | 1.40% 10-Q · filed 2016-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |